CRESCITA THERAPEUTICS INC (CTX.CA) Stock Fundamental Analysis

TSX:CTX • CA2258471028

0.49 CAD

0 (0%)

Last: Feb 19, 2026, 07:00 PM

Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

Fundamental Rating

Taking everything into account, CTX scores 4 out of 10 in our fundamental rating. CTX was compared to 33 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CTX as it has an excellent financial health rating, but there are worries on the profitability. CTX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability 2. Health 3. Growth 4. Valuation 5. Dividend

1. Profitability

1.1 Basic Checks

In the past year CTX was profitable.
In the past year CTX had a positive cash flow from operations.
In multiple years CTX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CTX reported negative operating cash flow in multiple years.

1.2 Ratios

CTX has a Return On Assets of 2.13%. This is in the better half of the industry: CTX outperforms 75.76% of its industry peers.
CTX's Return On Equity of 2.81% is fine compared to the rest of the industry. CTX outperforms 75.76% of its industry peers.

		Industry Rank	Sector Rank
ROA	2.13%
ROE	2.81%
ROIC	N/A

ROA(3y)-5.89%

ROA(5y)-4.27%

ROE(3y)-7.95%

ROE(5y)-5.81%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 2.07%, CTX is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
CTX has a better Gross Margin (51.77%) than 72.73% of its industry peers.
CTX's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	2.07%
GM	51.77%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.3%

GM growth 5Y-7.9%

More info and screens

ROA ROE ROIC Operating and Profit Margin Show most profitable peers

2. Health

2.1 Basic Checks

CTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CTX has less shares outstanding
Compared to 1 year ago, CTX has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -0.37, we must say that CTX is in the distress zone and has some risk of bankruptcy.
CTX has a Altman-Z score (-0.37) which is comparable to the rest of the industry.
There is no outstanding debt for CTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0.35
Altman-Z	-0.37

ROIC/WACCN/A

WACC8.39%

2.3 Liquidity

A Current Ratio of 3.12 indicates that CTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.12, CTX is doing good in the industry, outperforming 75.76% of the companies in the same industry.
CTX has a Quick Ratio of 2.07. This indicates that CTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.07, CTX belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.12
Quick Ratio	2.07

More info and screens

WACC Debt/Equity How to determine the health of a company Altman-Z score Show peers with great health

3. Growth

3.1 Past

CTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 117.32%, which is quite impressive.
Looking at the last year, CTX shows a very strong growth in Revenue. The Revenue has grown by 26.79%.
CTX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.60% yearly.

EPS 1Y (TTM)117.32%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%174.35%

Revenue 1Y (TTM)26.79%

Revenue growth 3Y5.3%

Revenue growth 5Y-2.6%

Sales Q2Q%50.06%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 24.50 indicates a rather expensive valuation of CTX.
75.76% of the companies in the same industry are more expensive than CTX, based on the Price/Earnings ratio.
CTX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.99.

		Industry Rank	Sector Rank
PE	24.5
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CTX indicates a rather cheap valuation: CTX is cheaper than 93.94% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CTX indicates a rather cheap valuation: CTX is cheaper than 87.88% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	6.52
EV/EBITDA	2.37

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Price/Earnings Price/FCF FCF per share EV/EBITDA PEG RATIO Show best valued peers

5. Dividend

5.1 Amount

No dividends for CTX!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks Show peers with best dividend

CRESCITA THERAPEUTICS INC

TSX:CTX (2/19/2026, 7:00:00 PM)

0.49

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-05 2025-11-05

Earnings (Next)03-16 2026-03-16

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners12.94%

Ins Owner ChangeN/A

Market Cap9.12M

Revenue(TTM)22.07M

Net Income(TTM)457.00K

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	24.5
Fwd PE	N/A
P/S	0.41
P/FCF	6.52
P/OCF	4.49
P/B	0.56
P/tB	0.62
EV/EBITDA	2.37

EPS(TTM)0.02

EY4.08%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.08

FCFY15.33%

OCF(TTM)0.11

OCFY22.29%

SpS1.19

BVpS0.87

TBVpS0.79

PEG (NY)N/A

PEG (5Y)N/A

Graham Number0.63

Profitability

		Industry Rank	Sector Rank
ROA	2.13%
ROE	2.81%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	2.07%
GM	51.77%
FCFM	6.34%

ROA(3y)-5.89%

ROA(5y)-4.27%

ROE(3y)-7.95%

ROE(5y)-5.81%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.3%

GM growth 5Y-7.9%

F-Score8

Asset Turnover1.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0.35
Debt/EBITDA	0
Cap/Depr	43.64%
Cap/Sales	2.88%
Interest Coverage	N/A
Cash Conversion	372.34%
Profit Quality	305.91%
Current Ratio	3.12
Quick Ratio	2.07
Altman-Z	-0.37

F-Score8

WACC8.39%

ROIC/WACCN/A

Cap/Depr(3y)37.08%

Cap/Depr(5y)28.12%

Cap/Sales(3y)2.6%

Cap/Sales(5y)2.05%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)117.32%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%174.35%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)26.79%

Revenue growth 3Y5.3%

Revenue growth 5Y-2.6%

Sales Q2Q%50.06%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y72.08%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y1647.5%

FCF growth 3YN/A

FCF growth 5Y-21.27%

OCF growth 1Y1594.17%

OCF growth 3YN/A

OCF growth 5Y-12.49%

CRESCITA THERAPEUTICS INC / CTX.CA FAQ

What is the ChartMill fundamental rating of CRESCITA THERAPEUTICS INC (CTX.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CTX.CA.

What is the valuation status of CRESCITA THERAPEUTICS INC (CTX.CA) stock?

ChartMill assigns a valuation rating of 3 / 10 to CRESCITA THERAPEUTICS INC (CTX.CA). This can be considered as Overvalued.

How profitable is CRESCITA THERAPEUTICS INC (CTX.CA) stock?

CRESCITA THERAPEUTICS INC (CTX.CA) has a profitability rating of 3 / 10.

What is the financial health of CRESCITA THERAPEUTICS INC (CTX.CA) stock?

The financial health rating of CRESCITA THERAPEUTICS INC (CTX.CA) is 8 / 10.